Search results
What's the Difference Between Ozempic and Wegovy?
Health via Yahoo News· 11 hours agoOzempic and Wegovy are GLP-1 medications that aim to improve blood sugar and obesity. While these drugs are similar, they differ in effectiveness and...
Eupraxia Pharmaceuticals expands trial of eosinophilic esophagitis therapy
Clinical Trials Arena via Yahoo Finance· 4 days agoEupraxia Pharmaceuticals has received approval from regulators in Australia and Canada to...
Sonos is returning the features its 'courageous' app redesign left behind
Tom's Guide· 3 days agoAfter weeks of getting yelled at from all corners of the internet, Sonos finally relented and is...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days ago- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 days agoFive clinical responses were observed, all in patients who previously received checkpoint inhibitors. A durable partial response (PR) in a patient with small-cell lung cancer ...
Motorola Razr (2024) series might get better without price increase: How is this possible?
PhoneArena· 5 days agoThe foldable phone scene is about to get a double dose of excitement with Motorola's upcoming...
Star USC scientist faces scrutiny — retracted papers and a paused drug trial
Boston Herald· 3 days agoLate last year, a group of whistle-blowers submitted a report to the National Institutes of Health...
Study Confirms: No Great Options for Treating VEXAS
MedPage Today· 4 days agoFor patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days ago- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients treated with EO2463 upon addition of lenalidomide ± rituximab - EO2463 rapidly expands memory CD8+ T cells specific
Leak suggests that DDR6 development has already started, aiming for 21 GT/s
Tom s Hardware· 5 days agoThe slide, the origin of which is unknown (yet it resembles slides from one of the major high-tech...